As the year draws to a close, it seems a natural time to reflect on the events of the past and dental biomaterial trends for the upcoming year in the world of dental biomaterials.
First, it is important to say “thank you” to all of our customers. It has been a pleasure to work with you, and we appreciate the trust you place in us. You use our dental biomaterials for your patients—because they work. Globally you have chosen our products for over two million patients and in 2018 we will celebrate 30 years in business. We hope to continue providing you with high quality osteobiologics and membranes to satisfy the clinical needs of your patients. We understand the science and biology of bone grafting, and have put together an informative glossary. To request yours, simply click here: https://mailchi.mp/c45ab150786b/weve-got-you-covered-bone-grafting-a-to-z-glossary
We understand the importance of keeping current as a dental provider. As we look forward to 2018, we need to keep in touch with the market and look at trends for the future. Here is an interesting fact: “According to a new series of reports on the Europe market for orthopedic biomaterials by iData Research, synthetic products are becoming the preferred products over allografts, demineralized bone matrices (DBMs) and autografts, due to their affordability and easy accessibility. A wide range of synthetic products can offer flexibility and variety for different groups of patients.1”
In early Q2, we will offer a new line of bone grafts designed to offer a faster remodeling profile. The product, Osseolive® is currently in a post-market clinical evaluation with a two month re-entry bone assessment time point. Osseolive should deliver one of the fastest remodeling products on the market.
We look forward to seeing more market trends at the industry meetings we will attend next year, including IAOCI and the Chicago Mid-Winter meeting –both in February. If you’ll be there, we hope to see you there!
We always appreciate your feedback. You can email us any time at email@example.com.
1IData Research Summary 6/16/17